Filing Details

Accession Number:
0001192482-20-000418
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-02 18:58:31
Reporting Period:
2020-06-01
Accepted Time:
2020-06-02 18:58:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1267565 Collegium Pharmaceutical Inc COLL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1443841 Joseph Ciaffoni C/O Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Stoughton MA 02072
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-06-01 4,672 $21.24 204,515 No 4 F Direct
Common Stock Acquisiton 2020-06-01 64,820 $8.22 269,335 No 4 M Direct
Common Stock Disposition 2020-06-01 70,576 $21.53 198,759 No 4 S Direct
Common Stock Disposition 2020-06-01 100 $22.08 198,659 No 4 S Direct
Common Stock Disposition 2020-06-02 5,761 $20.47 192,898 No 4 S Direct
Common Stock Disposition 2020-06-02 100 $21.30 192,798 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Purchase) Disposition 2020-06-01 64,820 $0.00 64,820 $8.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
64,821 2027-05-31 No 4 M Direct
Footnotes
  1. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.
  3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $22.02, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (3) and (4).
  4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.18 to $20.92, inclusive.
  5. 64,820 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer.